Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Lanz, Tobias V ^a,b,f   Williams, Sarah K ^b   Stojic, Aleksandar ^b   Iwantscheff, Simeon ^a   Sonner, Jana K ^a   Grabitz, Carl ^a   Becker, Simon ^a   Böhler, Laura Inés ^a   Mohapatra, Soumya R ^a   Sahm, Felix ^b   Küblbeck, Günter ^a   Nakamura, Toshikazu ^c   Funakoshi, Hiroshi ^d   Opitz, Christiane A ^a,b   Wick, Wolfgang ^a,b   Diem, Ricarda ^b   Platten, Michael ^a,b,e  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Neurogen Inc   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRYPTOPHAN 2,3 DIOXYGENASE;

ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CELL SURVIVAL; DEFICIENCY; DISEASE MODEL; ENZYMOLOGY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GLIA; IMMUNOLOGY; INFLAMMATION; LIVER; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULAR CLONING; MULTIPLE SCLEROSIS; NERVE CELL; NEUROPROTECTION; PATHOLOGY; PHENOTYPE; REPORTER GENE; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; CELL DIFFERENTIATION; CELL SURVIVAL; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENES, REPORTER; INFLAMMATION; LIVER; LYMPHOCYTE ACTIVATION; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; NEUROGLIA; NEURONS; NEUROPROTECTION; PHENOTYPE; T-LYMPHOCYTES; TRYPTOPHAN OXYGENASE;

EID: 85010770305     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep41271     Document Type: Article

References (57)

1. Sugimoto, H. et al. Crystal structure of human indoleamine 2, 3-dioxygenase: catalytic mechanism of O2 incorporation by a hemecontaining dioxygenase. Proc. Natl. Acad. Sci. USA 103, 2611-2616 (2006).
2. Zhang, Y. et al. Crystal structure and mechanism of tryptophan 2, 3-dioxygenase, a heme enzyme involved in tryptophan catabolism and in quinolinate biosynthesis. Biochemistry 46, 145-155 (2007).
3. Fujigaki, S. et al. Lipopolysaccharide induction of indoleamine 2, 3-dioxygenase is mediated dominantly by an IFN-gammaindependent mechanism. Eur. J. Immunol. 31, 2313-2318 (2001).
4. Lanz, T. V. et al. Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2, 3-dioxygenase 1 (IDO1). Stem Cells Dev. 19, 657-668 (2010).
5. Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity 22, 633-642 (2005).
6. Mezrich, J. D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190-3198 (2010).
7. Veldhoen, M. et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453, 106-109 (2008).
8. Quintana, F. J. et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453, 65-71 (2008).
9. Nguyen, N. T. et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. USA 107, 19961-19966 (2010).
10. Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197-203 (2011).
11. Pilotte, L. et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2, 3-dioxygenase. Proc. Natl. Acad. Sci. USA 109, 2497-2502 (2012).
12. Muller, A. J. et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2, 3 dioxygenase. Proc. Natl. Acad. Sci. USA 105, 17073-17078 (2008).
13. Platten, M., Wick, W. & Van den Eynde, B. J. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 72, 5435-5440 (2012).
14. Vacchelli, E. et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 3, e957994 (2014).
15. Yan, Y. et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J. Immunol. 185, 5953-5961 (2010).
16. Kwidzinski, E. et al. Indolamine 2, 3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J. 19, 1347-1349 (2005).
17. Sakurai, K., Zou, J.-P., Tschetter, J. R., Ward, J. M. & Shearer, G. M. Effect of indoleamine 2, 3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 129, 186-196 (2002).
18. Knox, W. E. & Mehler, A. H. The conversion of tryptophan to kynurenine in liver. I. The coupled tryptophan peroxidase-oxidase system forming formylkynurenine. J. Biol. Chem. 187, 419-430 (1950).
19. Minatogawa, Y., Suzuki, S., Ando, Y., Tone, S. & Takikawa, O. Tryptophan pyrrole ring cleavage enzymes in placenta. Adv. Exp. Med. Biol. 527, 425-434 (2003).
20. Tatsumi, K. et al. Induction of tryptophan 2, 3-dioxygenase in the mouse endometrium during implantation. Biochem. Biophys. Res. Commun. 274, 166-170 (2000).
21. Suzuki, S. et al. Expression of indoleamine 2, 3-dioxygenase and tryptophan 2, 3-dioxygenase in early concepti. Biochem. J. 355, 425-429 (2001).
22. Britan, A., Maffre, V., Tone, S. & Drevet, J. R. Quantitative and spatial differences in the expression of tryptophan-metabolizing enzymes in mouse epididymis. Cell Tissue Res. 324, 301-310 (2006).
23. Haber, R., Bessette, D., Hulihan-Giblin, B., Durcan, M. J. & Goldman, D. Identification of tryptophan 2, 3-dioxygenase RNA in rodent brain. J. Neurochem. 60, 1159-1162 (1993).
24. Wu, W. et al. Expression of tryptophan 2, 3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain. PLoS ONE 8, e59749 (2013).
25. Ohira, K. et al. Expression of tryptophan 2, 3-dioxygenase in mature granule cells of the adult mouse dentate gyrus. Mol Brain 3, 26 (2010).
26. Kanai, M. et al. Tryptophan 2, 3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain 2, 8 (2009).
27. Breda, C. et al. Tryptophan-2, 3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. Proc. Natl. Acad. Sci. USA 113, 5435-5440 (2016).
28. van der Goot, A. T. et al. Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc. Natl. Acad. Sci. USA 109, 14912-14917 (2012).
29. Campesan, S. et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr. Biol. 21, 961-966 (2011).
30. Trapp, B. D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
31. Ball, H. J., Jusof, F. F., Bakmiwewa, S. M., Hunt, N. H. & Yuasa, H. J. Tryptophan-catabolizing enzymes-party of three. Front Immunol 5, 485 (2014).
32. Platten, M., Knebel Doeberitz von, N., Oezen, I., Wick, W. & Ochs, K. Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors. Front Immunol 5, 673 (2014).
33. Grohmann, U., Fallarino, F. & Puccetti, P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24, 242-248 (2003).
34. Platten, M. et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. 310, 850-855 (2005).
35. Orsini, H. et al. GCN2 kinase plays an important role triggering the remission phase of experimental autoimmune encephalomyelitis (EAE) in mice. Brain Behav. Immun. 37, 177-186 (2014).
36. Keil, M. et al. General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation. J. Neuroimmunol. 297, 117-126 (2016).
37. Rothhammer, V. et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med. 22, 586-597 (2016).
38. Urenjak, J. & Obrenovitch, T. P. Neuroprotective potency of kynurenic acid against excitotoxicity. Neuroreport 11, 1341-1344 (2000).
39. Obrenovitch, T. P. & Urenjak, J. In vivo assessment of kynurenate neuroprotective potency and quinolinate excitotoxicity. Amino Acids 19, 299-309 (2000).
40. Zwilling, D. et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145, 863-874 (2011).
41. Guidetti, P. & Schwarcz, R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur. J. Neurosci. 11, 3857-3863 (1999).
42. Landwehrmeyer, G. B., Standaert, D. G., Testa, C. M., Penney, J. B. & Young, A. B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J. Neurosci. 15, 5297-5307 (1995).
43. Brandstätter, J. H., Koulen, P. & Wässle, H. Diversity of glutamate receptors in the mammalian retina. Vision Research 38, 1385-1397 (1998).
44. Ullian, E. M., Barkis, W. B., Chen, S., Diamond, J. S. & Barres, B. A. Invulnerability of retinal ganglion cells to NMDA excitotoxicity. Molecular and Cellular Neuroscience 26, 544-557 (2004).
45. DeParis, S., Caprara, C. & Grimm, C. Intrinsically photosensitive retinal ganglion cells are resistant to N-methyl-D-aspartic acid excitotoxicity. Mol. Vis. 18, 2814-2827 (2012).
46. Perkins, M. N. & Stone, T. W. Quinolinic acid: regional variations in neuronal sensitivity. Brain Research 259, 172-176 (1983).
47. Guillemin, G. J. Quinolinic acid, the inescapable neurotoxin. FEBS Journal 279, 1356-1365 (2012).
48. Baxter, A. G. The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 7, 904-912 (2007).
49. Sicotte, N. L. et al. Regional hippocampal atrophy in multiple sclerosis. Brain 131, 1134-1141 (2008).
50. Brissart, H. et al. Cognitive impairment among different clinical courses of multiple sclerosis. Neurological Research 35, 867-872 (2013).
51. Baban, B. et al. Indoleamine 2, 3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol. 61, 67-77 (2004).
52. Muyrers, J. P., Zhang, Y., Testa, G. & Stewart, A. F. Rapid modification of bacterial artificial chromosomes by ET-recombination. Nucleic Acids Res. 27, 1555-1557 (1999).
53. Angrand, P. O., Daigle, N., van der Hoeven, F., Schöler, H. R. & Stewart, A. F. Simplified generation of targeting constructs using ET recombination. Nucleic Acids Res. 27, e16 (1999).
54. Lanz, T. V. et al. Protein kinase C? as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 110, 14735-14740 (2013).
55. Storch, M. K. et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 8, 681-694 (1998).
56. Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676-682 (2012).
57. Fairless, R. et al. Preclinical retinal neurodegeneration in a model of multiple sclerosis. J. Neurosci. 32, 5585-5597 (2012).